Biotech

All Articles

Actinogen's cortisol blocker falls short phase 2 anxiety study

.Actinogen Medical's cortisol blocker has overlooked the key endpoint of a phase 2 research in anxie...

Bivictrix makes a decision going private only way to take ADC into facility

.Antibody-drug conjugates (ADCs) have been at the facility of a lot of a billion-dollar biobuck lice...

TPG leadings up funds to $580M for expenditures throughout lifestyle scientific researches

.Asset manager TPG, which has sustained biotechs such as Sionna Therapies and also Santa Clam Ana Bi...

Merck stops stage 3 TIGIT trial in lung cancer for futility

.Merck &amp Co.'s TIGIT system has gone through an additional obstacle. Months after shuttering a ph...

After a challenging year, Exscientia folds up into Recursion

.After a year defined by pipe cuts, the variation of its own chief executive officer as well as unem...

Cullinan, after $25M package, return bispecific to Port

.Cullinan Rehab was made an impression on sufficient with Harbour BioMed's bispecific immune system ...

A more detailed check out Ferocious Biotech's Ferocious 15

.Within this week's episode of "The Top Line," our team're diving in to Tough Biotech's annual Bruta...

Lilly deals with stage 2 breakdown of tau-targeting med

.The confetti is actually still soaring from Eli Lilly's gathering celebrating the approval of Alzhe...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of substantial leadership hirings, firings ...

Lykos will ask FDA to rethink its own choice following turndown of MDMA therapy for post-traumatic stress disorder

.Adhering to an unsatisfactory presenting for Lykos Therapies' MDMA prospect for post-traumatic stre...